Abbott Laboratories (ABT)
| Market Cap | 214.64B |
| Revenue (ttm) | 37.34B |
| Net Income (ttm) | 5.72B |
| Shares Out | 1.78B |
| EPS (ttm) | 3.55 |
| PE Ratio | 33.51 |
| Forward PE | 27.93 |
| Dividend | $1.71 |
| Dividend Yield | 1.44% |
| Trading Day | July 26 |
| Last Price | $118.96 |
| Previous Close | $120.80 |
| Change ($) | -1.84 |
| Change (%) | -1.52% |
| Day's Open | 120.24 |
| Day's Range | 118.62 - 120.49 |
| Day's Volume | 725,611 |
| 52-Week Range | 96.96 - 127.58 |
The US medical devices company Abbott Laboratories (NYSE:ABT) announced its fiscal Q2 results on Thursday before markets opened. The company posted higher than expected revenue of $10.22 billion, beatin...
Abbott's (ABT) Adult Nutrition sales benefit from improved sales performance of complete and balanced nutrition brand Ensure and diabetes nutrition brand, Glucerna in Q2.
Abbott (ABT) delivered earnings and revenue surprises of 15.84% and 5.13%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Abbott Laboratories (NYSE: ABT) Q2 profit more than doubled to $2.1 billion due to strength in its diagnostics business and a rebound in medical device sales. As curbs lift and vaccinations gather, dema...
Shares of Abbott Laboratories (NYSE:ABT) decreased 0.2% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share rose 105.26% over the past year to $1.17, which ...
Abbott Laboratories quarterly profit more than doubled on Thursday, due to strength in its diagnostics business and a rebound in medical devices sales.
ABBOTT PARK, Ill., July 22, 2021 /PRNewswire/ -- Abbott (NYSE: ABT) today announced financial results for the second quarter ended June 30, 2021.
Abbott Laboratories (NYSE:ABT) announces its next round of earnings this Thursday, July 22. Here is Benzinga's everything-that-matters guide for this Thursday's Q2 earnings announcement.
Abbott is scheduled to report its Q2 2021 results on Thursday, July 22. We expect Abbott to report revenues and earnings above the consensus estimates, driven by continued growth in diagnostics business...
These companies have earnings surprise track records and charts to envy.
In a world obsessed with price movements of stocks, it's easy to lose sight of what those prices represent -- the value of holding a company's future profit potential. One of the key ways that profit po...
Apart from COVIG-19 test related hiccups, Abbott (ABT) is likely to have suffered from significant sales decline within its pediatric nutrition business in Q2.
Abbott (ABT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Abbott (ABT) closed the most recent trading day at $117.17, moving -1.25% from the previous trading session.
Despite easing restrictions, COVID is going to be around a lot longer than many think.
PAHC vs. ABT: Which Stock Is the Better Value Option?
The stock price of Abbott Laboratories has seen an 11% rise over the last twenty-one trading days, while it is up 27% over the last year. Abbott has benefited from a strong demand for Covid-19 testing, ...
Snap up these three top stocks, WST, PAHC and RMD, which continue to show promise amid the pandemic and can turn out to be prudent investment choices.
While growth names still dominate the mainstream narrative, it's wise to consider some exposure to safety in dividend stocks. The post 7 Super-Safe Dividend Stock Performers to Buy appeared first on Inv...
Abbott Laboratories (NYSE: ABT) has begun laying off hundreds of workers at its diagnostic plants a month after it slashed its earnings forecasts for the remainder of 2021 amid diminishing demand for CO...
Snap up these three top stocks, WST, PAHC and RMD, which continue to show promise amid the pandemic and can turn out to be prudent investment choices.
Abbott (ABT) closed at $119.87 in the latest trading session, marking a +0.88% move from the prior day.
SAN FRANCISCO--(BUSINESS WIRE)--Francisco Partners, a leading global investment firm that specializes in partnering with technology businesses, today announced that it has signed a definitive agreement ...
With Independence Day now behind us and the second half of the year officially underway, investors are setting out their investment strategies for the back nine of 2021.
Abbott's (ABT) DAPT can be discontinued safely early as short as 28 days with no higher risk in patient adverse events.
Here are three stocks, BAX, BRBR, and MRVI with a favorable Zacks Rank and huge prospects in child healthcare at present.
Abbott (ABT) closed the most recent trading day at $115.93, moving -1.09% from the previous trading session.
Abbott's (ABT) Panbio COVID-19 Antigen Self-Test is expected to facilitate mass screenings and aid in resumption of daily life activities with the gradual reopening of economies worldwide.
Late-breaking data on Abbott's (ABT) FreeStyle Libre system demonstrates improvement in health and equity outcomes for diabetes patients.
ABBOTT PARK, Ill., June 30, 2021 /PRNewswire/ -- Abbott (NYSE: ABT) today announced its XIENCE family of stents has received U.S. Food and Drug Administration (FDA) approval for one-month (as short as 2...
They'll offer you growth -- and safety.
Some might be surprised to see income-paying stocks among the ARK Invest founder's high-growth picks.
ABBOTT PARK, Ill., June 25, 2021 /PRNewswire/ -- Abbott (NYSE: ABT) today announced late-breaking data that showed FreeStyle Libre, the world's leading7 continuous glucose monitoring (CGM) system, can s...
ABBOTT PARK, Ill., June 25, 2021 /PRNewswire/ -- Abbott (NYSE: ABT) will announce its second-quarter 2021 financial results on Thursday, July 22, 2021, before the market opens.
Bear of the Day: Abbott (ABT)
CGM device stocks Medtronic (MDT), Dexcom (DXCM) and Tandem Diabetes (TNDM) are expected to continue their run over the next few months.
Abbott (ABT) closed the most recent trading day at $111.70, moving +0.78% from the previous trading session.
PAHC vs. ABT: Which Stock Is the Better Value Option?
ABBOTT PARK, Ill., June 24, 2021 /PRNewswire/ -- A new Harris Poll survey finds the majority of adults in the U.S. who exercise intensely understand the importance of maintaining hydration throughout a ...
ABT, BNL, ITRG, JAZZ, and MANU have been added to the Zacks Rank #5 (Strong Sell) List on June 22, 2021
Texas Governor Greg Abbott somewhat amazingly declared during a recent press conference that the Texas electric grid was “better today than it's ever been.”
Abbott Earns First-of-its-Kind Recommendation for High School STEM Interns to Receive College Credit
ABBOTT PARK, Ill., June 22, 2021 /PRNewswire/ -- High school students who complete Abbott's award-winning summer internship program are now eligible to receive college credit for the experience in a fir...
We believe that there are other stocks in the healthcare sector that are currently better valued than Aboott Laboratories. Abbott's current price-to-operating income ratio (P/EBIT) of 30x is much higher...
According to Abbott (ABT), significant reductions in the number of COVID-19 cases in the United States and other major developed countries to hamper demand for COVID-19 testing in 2021.
In the latest trading session, Abbott (ABT) closed at $110.33, marking a -1.16% move from the previous day.
Don't wait to jump on this red-hot tech company and unstoppable dividend stock.
Despite recent struggles, the investment thesis for this company remains strong.
In the latest trading session, Abbott (ABT) closed at $110.48, marking a +0.52% move from the previous day.
About ABT
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidi... [Read more...]
| Industry Medical Devices | Founded 1888 |
| CEO Robert Ford | Employees 109,000 |
| Stock Exchange NYSE | Ticker Symbol ABT |
Financial Performance
In 2020, ABT's revenue was $34.61 billion, an increase of 8.48% compared to the previous year's $31.90 billion. Earnings were $4.50 billion, an increase of 21.91%.
Analyst Forecasts
According to 21 analysts, the average rating for ABT stock is "Buy." The 12-month stock price forecast is 125.95, which is an increase of 5.88% from the latest price.